Godman, Brian and Wild, Claudia and Haycox, Alan (2017) Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

[1]  M. Lamfers,et al.  Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US , 2017 .

[2]  Andrew Hill,et al.  Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis , 2017, BMJ Open.

[3]  C. Wild,et al.  Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? , 2016, ESMO Open.

[4]  B. Godman,et al.  Utilisation of the ESMO-MCBS in practice of HTA. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. L. Specchia,et al.  Links between Pharmaceutical R&D Models and Access to Affordable Medicines , 2016 .

[6]  R. Malmström,et al.  Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe , 2015, Expert review of pharmacoeconomics & outcomes research.

[7]  James Allison,et al.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. , 2015, Mayo Clinic proceedings.

[8]  E. Berndt,et al.  Pricing in the Market for Anticancer Drugs , 2014, The journal of economic perspectives : a journal of the American Economic Association.

[9]  Thomas J. Smith,et al.  Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. , 2014, The Lancet. Oncology.

[10]  T. Fojo,et al.  Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Bach.  Reforming the payment system for medical oncology. , 2013, JAMA.

[12]  A. Haycox,et al.  Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs , 2013, Front. Pharmacol..

[13]  A. Kesselheim,et al.  The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs , 2012, PloS one.